Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/09/26
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)PRNewsWire • 03/06/26
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza GuidanceBenzinga • 02/12/26
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/11/26
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026PRNewsWire • 02/11/26
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPSZacks Investment Research • 02/06/26
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive DyskinesiaPRNewsWire • 01/26/26
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial ResultsPRNewsWire • 01/21/26
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XRPRNewsWire • 01/15/26
Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/26
Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited DamageBenzinga • 12/23/25
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral PalsyPRNewsWire • 12/22/25
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs TranscriptSeeking Alpha • 12/17/25
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and EndocrinologyPRNewsWire • 12/16/25